

# Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

## ES-2

RRID:CVCL\_3509

Type: Cell Line

### Proper Citation

RRID:CVCL\_3509

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_3509](https://web.expasy.org/cellosaurus/CVCL_3509)

**Proper Citation:** RRID:CVCL\_3509

**Description:** Cell line ES-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Ovarian clear cell adenocarcinoma

**Defining Citation:** [PMID:1717140](#), [PMID:9698466](#), [PMID:11103784](#), [PMID:12960427](#), [PMID:16382445](#), [PMID:17671176](#), [PMID:18560578](#), [PMID:18720132](#), [PMID:20081105](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22328975](#), [PMID:22460905](#), [PMID:22705003](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25049276](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26388441](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

**Comments:** Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Probably misclassified. It is dubious that this cell line originates from an African American 47 year old patient diagnosed with an ovarian clear cell adenocarcinoma. Immunohistochemical and qPCR analysis as well as its mutational profile support an ovarian serous adenocarcinoma origin (PubMed=25049276; DOI=10.26502/ogr072). Furthermore its genome ancestry clearly shows a Caucasian/European decent (PubMed=30894373) which is confirmed by mtDNA haplotyping (DOI=10.26502/ogr072)..

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** ES-2

**Synonyms:** ES2

**Cross References:** BTO:BTO\_0004424, CLO:CLO\_0002947, EFO:EFO\_0002177, AddexBio:C0017006/4971, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1978, BCRC:60067, BCRJ:0080, BioGRID\_ORCS\_Cell\_line:435, BioSample:SAMN02800400, BioSample:SAMN03472439, BioSample:SAMN10988319, cancercellines:CVCL\_3509, CCRID:1101HUM-PUMC000371, CCRID:3101HUMTCHu111, CCRID:4201HUM-CCTCC00322, CCTCC:GDC0322, Cell\_Model\_Passport:SIDM00861, CGH-DB:323-2, CLS:305038, Cosmic:844353, Cosmic:897429, Cosmic:1044235, Cosmic:1102814, Cosmic:1113277, Cosmic:1139225, Cosmic:1223312, Cosmic:1305327, Cosmic:1312191, Cosmic:1328071, Cosmic:1450145, Cosmic:1708382, Cosmic:1709256, Cosmic:1995396, Cosmic:2074240, Cosmic-CLP:1240128, DepMap:ACH-000906, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240128, GEO:GSM95455, GEO:GSM274699, GEO:GSM313713, GEO:GSM383926, GEO:GSM416675, GEO:GSM659376, GEO:GSM784563, GEO:GSM887008, GEO:GSM888077, GEO:GSM1001491, GEO:GSM1176276, GEO:GSM1291140, GEO:GSM1340580, GEO:GSM1341129, GEO:GSM1669769, GEO:GSM2474975, IARC\_TP53:28314, IGRhCellID:ES2, LiGeA:CCE\_094, LINCS\_LDP:LCL-1806, PharmacDB:ES2\_337\_2019, PRIDE:PXD000901, PRIDE:PXD030304, Progenetix:CVCL\_3509, Ubigen:YC-C139, Wikidata:Q54832435

**ID:** CVCL\_3509

**Record Creation Time:** 20220427T215835+0000

**Record Last Update:** 20260829T232616+0000

---

## Ratings and Alerts

No rating or validation information has been found for ES-2.

No alerts have been found for ES-2.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 353 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Khetan R, et al. (2026) The gut microbiota regulates the protein corona formation, biodistribution, and cellular uptake of lipid nanoparticles. Journal of controlled release : official journal of the Controlled Release Society, 395, 114995.

Zhang F, et al. (2026) The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. *Oncogenesis*, 15(1).

Chen Y, et al. (2026) The translation landscape of ovarian clear cell carcinoma indicates that RBM4 plays a pro-oncogenic role in tumor progression. *Oncogene*, 45(27), 2714.

Lin C, et al. (2026) Enterolactone and THBS1-3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment. *British journal of pharmacology*, 183(11), 2837.

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). *EMBO molecular medicine*, 18(5), 1933.

Mortan LF, et al. (2026) Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. *Cells*, 15(3).

Uno K, et al. (2026) Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. *Science advances*, 12(6), eadu5944.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. *British journal of pharmacology*.

Huang B, et al. (2026) The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. *Cell death & disease*, 17(1), 202.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Lin CY, et al. (2026) Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. *Journal of molecular medicine (Berlin, Germany)*, 104(1), 33.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. *Cell reports*, 45(4), 117198.

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. *NPJ precision oncology*, 9(1), 3.

Schott A, et al. (2025) The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer. *NAR cancer*, 7(1), zcaf006.

Borrelli MJ, et al. (2025) Spatiotemporal analysis of ratiometric biosensors in live multicellular spheroids using SPoRTS. *Cell reports methods*, 5(2), 100987.

Sun X, et al. (2025) Placental extracellular vesicles induce ovarian tumour cell death in an ex vivo explant model: Possible therapeutic potential. *Placenta*, 160, 20.

Ding C, et al. (2025) A Tumor-homing nanoplatfrom for the co-delivery of triptolide and siRNA-A4B2 conspicuously overcomes peritoneum metastasis of ovarian cancer. *Cellular oncology (Dordrecht, Netherlands)*, 48(6), 1741.

Liao Q, et al. (2025) p53 induces circFRMD4A to suppress cancer development through glycolytic reprogramming and cuproptosis. *Molecular cell*, 85(1), 132.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.